Evidence map›Paper›PMID 26840426›Full record

ArticlePloS one2016

Different Effects of Three Selected Lactobacillus Strains in Dextran Sulfate Sodium-Induced Colitis in BALB/c Mice.

Yi Cui, Hongyun Wei, Fanggen Lu, Xiaowei Liu, Deliang Liu, Li Gu, Chunhui Ouyang

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Optimization of dextran sulfate sodium-induced colitis and associated mortality in BALB/c mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Characteristics ofMicrobiology spectrum · 2024
    Article
  8. Article
  9. Different Effects of DifferentInternational journal of molecular sciences · 2022
    Article
  10. Article
  11. Protective Effect ofFoods (Basel, Switzerland) · 2020
    Article
  12. Review
  13. Article
  14. Article
  15. ImmunobioticFrontiers in immunology · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yi CuiDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Hongyun WeiDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Fanggen LuDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Xiaowei LiuDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Deliang LiuDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Li GuDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.
Chunhui OuyangDepartment of Gastroenterology, The Second Xiangya Hospital of Central South University, Changsha, Hunan Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo analyze the changes of different Lactobacillus species in ulcerative colitis patients and to further assess the therapeutic effects of selected Lactobacillus strains on dextran sulfate sodium (DSS)-induced experimental colitis in BALB/c mice.

methodsForty-five active ulcerative colitis (UC) patients and 45 population-based healthy controls were enrolled. Polymerase chain reaction (PCR) amplification and real-time PCR were performed for qualitative and quantitative analyses, respectively, of the Lactobacillus species in UC patients. Three Lactobacillus strains from three species were selected to assess the therapeutic effects on experimental colitis. Sixty 8-week-old BALB/c mice were divided into six groups. The five groups that had received DSS were administered normal saline, mesalazine, L. fermentum CCTCC M206110 strain, L. crispatus CCTCC M206119 strain, or L. plantarum NCIMB8826 strain. We assessed the severity of colitis based on disease activity index (DAI), body weight loss, colon length, and histologic damage.

resultsThe detection rate of four of the 11 Lactobacillus species decreased significantly (P < 0.05), and the detection rate of two of the 11 Lactobacillus species increased significantly (P < 0.05) in UC patients. Relative quantitative analysis revealed that eight Lactobacillus species declined significantly in UC patients (P < 0.05), while three Lactobacillus species increased significantly (P < 0.05). The CCTCC M206110 treatment group had less weight loss and colon length shortening, lower DAI scores, and lower histologic scores (P < 0.05), while the CCTCC M206119 treatment group had greater weight loss and colon length shortening, higher histologic scores, and more severe inflammatory infiltration (P < 0.05). NCIMB8826 improved weight loss and colon length shortening (P < 0.05) with no significant influence on DAI and histologic damage in the colitis model.

conclusionsAdministration of an L. crispatus CCTCC M206119 supplement aggravated DSS-induced colitis. L. fermentum CCTCC M206110 proved to be effective at attenuating DSS-induced colitis. The potential probiotic effect of L. plantarum NCIMB8826 on UC has yet to be assessed.

Indexed as

Disease Models, AnimalAdultAnimalsColitis, UlcerativeColonDextran SulfateDietary SupplementsFecesFemaleGastrointestinal MicrobiomeHumansLactobacillusMaleMiceMice, Inbred BALB CProbioticsDextran Sulfate

Identifiers

PMID26840426
PMCPMC4739695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.